Pharvaris N.V.

Last updated September 27, 2026

Organization details

Legal name
Pharvaris N.V.
Ownership
Public
Status
Active
Headquarters country
Netherlands
Ticker symbol
PHVS
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001830487

Board of directors

Chief executives

Berndt Modig · Chief Executive Officer
Since March 2026

Board connections

3 of this board's directors also sit on 5 other boards.

Network of Pharvaris N.V.'s board connections ADC Therapeutics SA ADC Therapeutics SA Kardigan Inc. Kardigan Inc. Rhythm Pharmaceuticals Inc. Rhythm Pharmaceuticals... Rocket Pharmaceuticals Inc. Rocket Pharmaceuticals... Trevi Therapeutics Inc. Trevi Therapeutics Inc... David P. Meeker David P. Meeker Elisabeth Bjork Elisabeth Bjork Viviane Monges Viviane Monges Pharvaris N.V.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$33,020,993
71 sales by 11 insiders
Date Insider Transaction Shares Price Value
Sep 23, 2026 Viviane Monges Director Option exercise +11,969 $8.05 $96,350
Sep 23, 2026 Viviane Monges Director Open-market sale −11,969 $33.05 $395,524
Sep 22, 2026 Lu Peng Officer (President) Option exercise +45,308 $2.59 $117,348
Sep 22, 2026 Johannes Gerardus Christiaan Petrus Schikan Director Option exercise +800 $20.00 $16,000
Sep 22, 2026 Johannes Gerardus Christiaan Petrus Schikan Director Open-market sale −800 $36.19 $28,952
Sep 21, 2026 Nassif David W. Officer (CFO / CLO) Open-market sale −6,000 $36.47 $218,801
Sep 21, 2026 Nassif David W. Officer (CFO / CLO) Gift −500 — —
Sep 17, 2026 Elisabeth Bjork Director Option exercise +35,000 $14.39 $503,650
Sep 17, 2026 Robert Glassman Director Option exercise +14,493 $18.14 $262,903
Sep 17, 2026 Lesage Anne Officer (Chief Early Development) Open-market sale −20,000 $38.27 $765,466
Sep 17, 2026 Lu Peng Officer (President) Option exercise +100,000 $2.59 $259,000
Sep 17, 2026 Berndt Modig Director, Officer (Chief Executive Officer) Option exercise −300,000 $35.00 $10,500,000
Sep 17, 2026 Johannes Gerardus Christiaan Petrus Schikan Director Open-market sale −200,000 $35.00 $7,000,000
Sep 17, 2026 Elisabeth Bjork Director Option exercise +17,500 $18.14 $317,450
Sep 17, 2026 Robert Glassman Director Open-market sale −14,493 $38.56 $558,812

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.